Vensica Medical Receives FDA IND Clearance to Initiate Phase 2 Study of ViXe, Its Needle-Free Xeomin® Delivery System for Overactive Bladder

Contributed by: Business Wire

Logo

Images

Avner Geva, Cofounder, CEO (left), and Avi Eftel, Cofounder, CTO (right)

Business Wire embedded0

Tags

Biotechnology

Pharmaceutical

Surgery

General Health

Health

FDA

Medical Devices

Clinical Trials

Xeomin

More Like This

PR Newswire associated0

Pierre Fabre Laboratories announce granting of European marketing authorization for OBGEMSA™ (vibegron) in overactive bladder.

Gynica announces First-in-Human Clinical Trial of Novel IntraVag© Treatment for Endometriosis

PR Newswire associated0

Pierre Fabre Laboratories receive positive CHMP opinion for OBGEMSA™(vibegron) in overactive bladder syndrome

Merz Therapeutics Submits Application to the European Medicines Agency for New Indication of XEOMIN® in Pediatric Spasticity

Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures

/C O R R E C T I O N -- Gesynta Pharma/

PR Newswire associated0

UroMems Receives Clearance from the FDA and the French ANSM for Initiating Landmark Pivotal Clinical Study of UroActive® Smart Implant to Treat Male Stress Urinary Incontinence

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week